MA32134B1 - Composés hétérocycliques - Google Patents
Composés hétérocycliquesInfo
- Publication number
- MA32134B1 MA32134B1 MA33139A MA33139A MA32134B1 MA 32134 B1 MA32134 B1 MA 32134B1 MA 33139 A MA33139 A MA 33139A MA 33139 A MA33139 A MA 33139A MA 32134 B1 MA32134 B1 MA 32134B1
- Authority
- MA
- Morocco
- Prior art keywords
- heterocyclic compounds
- compounds
- substituents
- salts
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Abstract
Cette invention concerne des composés de formule i et leurs sels, les substituants étant tels que définis dans la description, ainsi que des procédés permettant de les préparer; des composés pharmaceutiques contenant ces composés, en particulier pour une utilisation dans le cadre d'une ou plusieurs maladies associées avec la tyrosine kinase.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08151137 | 2008-02-06 | ||
PCT/EP2009/051281 WO2009098236A1 (fr) | 2008-02-06 | 2009-02-04 | Composés hétérocycliques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32134B1 true MA32134B1 (fr) | 2011-03-01 |
Family
ID=39739330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33139A MA32134B1 (fr) | 2008-02-06 | 2010-09-02 | Composés hétérocycliques |
Country Status (27)
Country | Link |
---|---|
US (1) | US8420657B2 (fr) |
EP (1) | EP2247591A1 (fr) |
JP (1) | JP5323095B2 (fr) |
KR (2) | KR20130066703A (fr) |
CN (1) | CN101981036B (fr) |
AR (1) | AR070558A1 (fr) |
AU (1) | AU2009211338B2 (fr) |
BR (1) | BRPI0908433A2 (fr) |
CA (1) | CA2714177A1 (fr) |
CL (1) | CL2009000255A1 (fr) |
CO (1) | CO6321262A2 (fr) |
CR (1) | CR11614A (fr) |
DO (1) | DOP2010000242A (fr) |
EA (1) | EA017952B1 (fr) |
EC (1) | ECSP10010463A (fr) |
IL (1) | IL207224A0 (fr) |
MA (1) | MA32134B1 (fr) |
MX (1) | MX2010008719A (fr) |
NI (1) | NI201000137A (fr) |
NZ (1) | NZ587271A (fr) |
PA (1) | PA8815201A1 (fr) |
PE (1) | PE20091485A1 (fr) |
SM (1) | SMP201000104B (fr) |
TW (1) | TW200938202A (fr) |
UY (1) | UY31631A1 (fr) |
WO (1) | WO2009098236A1 (fr) |
ZA (1) | ZA201005338B (fr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
WO2009114533A2 (fr) * | 2008-03-10 | 2009-09-17 | Cornell University | Modulation de la perméabilité d'une barrière hématoencéphalique |
WO2010020675A1 (fr) | 2008-08-22 | 2010-02-25 | Novartis Ag | Composés de pyrrolopyrimidine et leurs utilisations |
US8518933B2 (en) * | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
US8546377B2 (en) | 2009-04-23 | 2013-10-01 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
WO2010124042A2 (fr) * | 2009-04-23 | 2010-10-28 | Abbott Laboratories | Modulateurs des récepteurs 5-ht et méthodes d'utilisation de ceux-ci |
AR078675A1 (es) | 2009-10-20 | 2011-11-23 | Cellzome Ltd | Derivados de pirazolo[3,4-d]pirimidina inhibidores de jak quinasas, composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos para el tratamiento o profilaxis de trastornos inmunologicos, inflamatorios y autoinmunes. |
JP5607174B2 (ja) * | 2009-12-01 | 2014-10-15 | アッヴィ・インコーポレイテッド | 新規な三環式化合物 |
US8791100B2 (en) | 2010-02-02 | 2014-07-29 | Novartis Ag | Aryl benzylamine compounds |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
UY33226A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
EP2566867A1 (fr) * | 2010-04-30 | 2013-03-13 | Cellzome Limited | Composés de pyrazole comme inhibiteurs de jak |
TW201204732A (en) | 2010-07-09 | 2012-02-01 | Leo Pharma As | Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
WO2012022681A2 (fr) | 2010-08-20 | 2012-02-23 | Cellzome Limited | Analogues de la hétérocyclyl pyrazolopyrimidine comme inhibiteurs sélectifs de la jak |
CN103221535A (zh) * | 2010-09-16 | 2013-07-24 | 康奈尔大学 | 腺苷受体信号转导调节血脑屏障通透性的用途 |
WO2012143320A1 (fr) | 2011-04-18 | 2012-10-26 | Cellzome Limited | Composés (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine comme inhibiteurs de la jak3 |
JP5832647B2 (ja) | 2011-07-01 | 2015-12-16 | ノバルティス アーゲー | がんの治療における使用のためのcdk4/6阻害剤およびpi3k阻害剤を含む併用療法 |
JP2014531449A (ja) * | 2011-09-20 | 2014-11-27 | セルゾーム リミティッド | キナーゼ阻害剤としてのピラゾロ[4,3―c]ピリジン誘導体 |
CN103945850A (zh) | 2011-11-15 | 2014-07-23 | 诺华股份有限公司 | 磷酸肌醇-3-激酶抑制剂与Janus激酶2-信号转导和转录激活因子5通路的调节剂的组合 |
CN102627646A (zh) * | 2012-03-19 | 2012-08-08 | 苏州四同医药科技有限公司 | 一种3-碘-5-溴-4,7-二氮杂吲哚的制备方法 |
CN102633802B (zh) * | 2012-04-11 | 2014-03-19 | 南京药石药物研发有限公司 | 一种合成2-氯-7H-吡咯并[2,3-d]嘧啶的中间体及其制法 |
CN106008511B (zh) * | 2012-05-14 | 2018-08-14 | 华东理工大学 | 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用 |
CN103059030B (zh) * | 2012-12-28 | 2015-04-29 | 北京师范大学 | 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用 |
WO2014145576A2 (fr) | 2013-03-15 | 2014-09-18 | Northwestern University | Pyrrolo(2,3-d)pyrimidines substituées pour le traitement du cancer |
WO2015143692A1 (fr) * | 2014-03-28 | 2015-10-01 | Changzhou Jiekai Pharmatech Co., Ltd. | Composés hétérocycliques en tant qu'inhibiteurs d'axl |
KR102139847B1 (ko) | 2014-05-01 | 2020-07-31 | 노파르티스 아게 | 톨-유사 수용체 7 효능제로서의 화합물 및 조성물 |
BR112016025048A2 (pt) * | 2014-05-01 | 2017-10-31 | Novartis Ag | compostos e composições como agonistas do receptor tipo toll7 |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
UA127925C2 (uk) | 2018-03-30 | 2024-02-14 | Інсайт Корпорейшн | Лікування гнійного гідраденіту з використанням інгібіторів jak |
CN111484496B (zh) * | 2019-01-29 | 2022-11-29 | 江苏开元药业有限公司 | 2-氨基-吡咯并嘧啶和吡唑并嘧啶类化合物及其制备方法和用途 |
WO2020227563A1 (fr) | 2019-05-08 | 2020-11-12 | Vimalan Biosciences, Inc. | Inhibiteurs de jak |
CN110305140B (zh) * | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
KR20220051351A (ko) | 2019-08-08 | 2022-04-26 | 비말란 바이오사이언스즈, 인크. | Jak 억제제 |
GB201911868D0 (en) * | 2019-08-19 | 2019-10-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
WO2021050700A1 (fr) * | 2019-09-13 | 2021-03-18 | The Broad Institute, Inc. | Inhibiteurs de cyclo-oxygénase 2 et leurs utilisations |
GB201914910D0 (en) * | 2019-10-15 | 2019-11-27 | Sentinel Oncology Ltd | Pharmaceutical compounds |
WO2023036252A1 (fr) * | 2021-09-08 | 2023-03-16 | 希格生科(深圳)有限公司 | Dérivé de pyrrolopyrimidine ou de pyrrolopyridine et son utilisation médicale |
CN114957248B (zh) * | 2022-05-09 | 2023-12-29 | 南开大学 | 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7917643B2 (en) * | 1996-09-12 | 2011-03-29 | Audible, Inc. | Digital information library and delivery system |
US20030074530A1 (en) * | 1997-12-11 | 2003-04-17 | Rupaka Mahalingaiah | Load/store unit with fast memory data access mechanism |
US6887224B2 (en) * | 1998-06-15 | 2005-05-03 | Ilse Rubio | Close fitting leakage resistant feminine hygiene pad |
HUP0102574A3 (en) | 1998-06-19 | 2002-01-28 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds |
JP4078074B2 (ja) | 1999-12-10 | 2008-04-23 | ファイザー・プロダクツ・インク | ピロロ[2,3−d]ピリミジン化合物 |
WO2002076985A1 (fr) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Composes utiles en tant qu'inhibiteurs de kinases pour le traitement des maladies hyperproliferatives |
CN100386328C (zh) | 2002-03-07 | 2008-05-07 | 霍夫曼-拉罗奇有限公司 | 双环吡啶和嘧啶p38激酶抑制剂 |
US7132221B2 (en) * | 2003-09-12 | 2006-11-07 | Headway Technologies, Inc. | Method to print photoresist lines with negative sidewalls |
US7532909B2 (en) * | 2003-10-15 | 2009-05-12 | Nextel Communications Inc. | System and method for providing dedicated paging channels for walkie-talkie services |
US7319102B1 (en) | 2003-12-09 | 2008-01-15 | The Procter & Gamble Company | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors |
US7968557B2 (en) * | 2004-02-14 | 2011-06-28 | Novartis Ag | Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors |
CN1926140A (zh) | 2004-03-05 | 2007-03-07 | 大正制药株式会社 | 吡咯并嘧啶衍生物 |
WO2005107760A1 (fr) * | 2004-04-30 | 2005-11-17 | Irm Llc | Composes et compositions en tant qu'inducteurs de la differenciation de keratinocytes |
KR20070085286A (ko) * | 2004-10-29 | 2007-08-27 | 티보텍 파마슈티칼즈 리미티드 | Hiv를 저해하는 바이사이클릭 피리미딘 유도체 |
US20060122003A1 (en) * | 2004-12-03 | 2006-06-08 | Kim Jong H | Portable golf swing position training aid kit |
ES2411975T3 (es) | 2005-01-14 | 2013-07-09 | Janssen Pharmaceutica Nv | Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas |
MX2007009429A (es) * | 2005-02-03 | 2008-03-18 | Vertex Pharma | Pirrolopirimidinas utiles como inhibidores de proteinas cinasas. |
JP2006241089A (ja) | 2005-03-04 | 2006-09-14 | Astellas Pharma Inc | ピロロピリミジン誘導体またはその塩 |
EP1877411B9 (fr) | 2005-05-05 | 2012-08-29 | Ardea Biosciences, Inc. | Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih |
US7749527B2 (en) | 2005-05-24 | 2010-07-06 | Wyeth Llc | Gel compositions for control of ecto-parasites |
EP1948658A1 (fr) | 2005-10-13 | 2008-07-30 | Glaxo Group Limited | Dérivés de la pyrrolopyrimidine inhibiteurs de la syk |
DK1951724T3 (da) | 2005-11-17 | 2011-08-15 | Osi Pharmaceuticals Llc | Sammensmeltede bicykliske mTOR-inhibitorer |
PL2474545T3 (pl) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corporation | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
AU2007227210A1 (en) | 2006-03-20 | 2007-09-27 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
JP4861772B2 (ja) * | 2006-08-28 | 2012-01-25 | 富士通株式会社 | 移動体標定プログラム、該プログラムを記録した記録媒体、移動体標定装置、および移動体標定方法 |
CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
KR20090033605A (ko) * | 2007-10-01 | 2009-04-06 | 삼성전자주식회사 | 적층형 반도체 패키지, 그 형성방법 및 이를 구비하는전자장치 |
WO2009070524A1 (fr) | 2007-11-27 | 2009-06-04 | Wyeth | Composés de pyrrolo[3,2-d]pyrimidine et leur utilisation comme inhibiteurs de la pi3 kinase et de la mtor kinase |
CN101945867A (zh) | 2007-12-19 | 2011-01-12 | 安姆根有限公司 | 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物 |
US20090192176A1 (en) | 2008-01-30 | 2009-07-30 | Wyeth | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
-
2009
- 2009-02-04 NZ NZ587271A patent/NZ587271A/en not_active IP Right Cessation
- 2009-02-04 UY UY031631A patent/UY31631A1/es not_active Application Discontinuation
- 2009-02-04 KR KR1020137011455A patent/KR20130066703A/ko not_active Application Discontinuation
- 2009-02-04 EP EP09708802A patent/EP2247591A1/fr not_active Withdrawn
- 2009-02-04 PE PE2009000162A patent/PE20091485A1/es not_active Application Discontinuation
- 2009-02-04 CA CA2714177A patent/CA2714177A1/fr not_active Abandoned
- 2009-02-04 WO PCT/EP2009/051281 patent/WO2009098236A1/fr active Application Filing
- 2009-02-04 EA EA201001242A patent/EA017952B1/ru not_active IP Right Cessation
- 2009-02-04 JP JP2010545458A patent/JP5323095B2/ja not_active Expired - Fee Related
- 2009-02-04 MX MX2010008719A patent/MX2010008719A/es active IP Right Grant
- 2009-02-04 BR BRPI0908433A patent/BRPI0908433A2/pt not_active IP Right Cessation
- 2009-02-04 AR ARP090100362A patent/AR070558A1/es not_active Application Discontinuation
- 2009-02-04 CN CN2009801117630A patent/CN101981036B/zh not_active Expired - Fee Related
- 2009-02-04 KR KR1020107019690A patent/KR101277823B1/ko not_active IP Right Cessation
- 2009-02-04 AU AU2009211338A patent/AU2009211338B2/en not_active Ceased
- 2009-02-05 CL CL2009000255A patent/CL2009000255A1/es unknown
- 2009-02-05 US US12/366,218 patent/US8420657B2/en not_active Expired - Fee Related
- 2009-02-05 TW TW098103755A patent/TW200938202A/zh unknown
- 2009-02-05 PA PA20098815201A patent/PA8815201A1/es unknown
-
2010
- 2010-07-26 IL IL207224A patent/IL207224A0/en unknown
- 2010-07-27 ZA ZA2010/05338A patent/ZA201005338B/en unknown
- 2010-07-29 CR CR11614A patent/CR11614A/es not_active Application Discontinuation
- 2010-08-04 DO DO2010000242A patent/DOP2010000242A/es unknown
- 2010-08-04 NI NI201000137A patent/NI201000137A/es unknown
- 2010-09-02 MA MA33139A patent/MA32134B1/fr unknown
- 2010-09-02 SM SM201000104T patent/SMP201000104B/it unknown
- 2010-09-06 EC EC2010010463A patent/ECSP10010463A/es unknown
- 2010-09-06 CO CO10110021A patent/CO6321262A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32134B1 (fr) | Composés hétérocycliques | |
MA38391A1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
MA32306B1 (fr) | Derives de quinoleines et de quinoxalines en tant qu'inhibiteurs de proteine tyrosine kinases | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
MA31433B1 (fr) | Inhibiteurs de la p70 s6 kinase | |
MA30405B1 (fr) | Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3 | |
MA47043B1 (fr) | Composés indole carboxamides utiles comme inhibiteurs de kinase | |
MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
MA30291B1 (fr) | Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale | |
MA34300B1 (fr) | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 | |
MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA31339B1 (fr) | Dérivés hétérobicycliques de pyrazole et méthodes d'utilisation | |
MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
MA34299B1 (fr) | Dérivés d'aminopyrimidine au titre de modulateurs de lrrk2 | |
MA37891A1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
MA29856B1 (fr) | Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases | |
MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
MA29795B1 (fr) | Inhibiteurs de la dipeptidyl peptidase permetttant de traiter le diabete | |
MA31903B1 (fr) | Derives de thiazole utilises comme inhibiteur de la pi 3 kinase | |
MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
ATE527253T1 (de) | Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer | |
MA31741B1 (fr) | Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide | |
MA34559B1 (fr) | Formulation pour le traitement du cancer | |
MA29909B1 (fr) | Derives de pyridazine |